Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Supplementary Figures 1-15 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
2. 2Supplementary Figures 1-15 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
3. 3Data from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
4. 4DMG-45. Single-nucleus profiling of postmortem diffuse midline gliomas identifies mitochondrial biogenesis as a resistance mechanism to imipridone therapy.Original Research · 2025
5. 5DMG-30. ONC201 induces immune-tumor surveillance and alters the tumor immune microenvironment of diffuse midline glioma modelsClinical Trial · 2025